27 studies found for:    " March 03, 2010":" April 02, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men
Conditions: HIV Prevention;   HIV Infections
Intervention: Drug: Raltegravir
2 Completed Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
Conditions: HIV-1 Infection;   HIV Infections
Intervention: Biological: PENNVAX-B
3 Active, not recruiting
Has Results
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
4 Recruiting Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection
Conditions: HIV;   HIV Infections
Intervention:
5 Completed
Has Results
Study of Vitamin D and Effect on Heart Disease and Insulin Resistance
Conditions: HIV;   Vitamin D Deficiency;   HIV Infections
Intervention: Drug: Vitamin D
6 Unknown  Sustiva Levels With Use of a Gel Capsule
Conditions: HIV;   HIV Infections
Interventions: Drug: Efavirenz;   Drug: Over-encapsulated efavirenz
7 Completed
Has Results
HIV and Fat Accumulation
Condition: HIV Infection
Intervention: Drug: Telmisartan
8 Completed TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients
Condition: HIV-Infections
Intervention: Drug: etravirine
9 Completed
Has Results
Vitamin D Dose Finding Study
Conditions: HIV Infections;   AIDS
Intervention: Drug: Cholecalciferol (Vit D3)
10 Active, not recruiting Using Incentives to Improve Parolee Participation and Attendance in Community Treatment
Conditions: Substance Abuse;   HIV Infections
Interventions: Behavioral: Contingency management: voucher/monetary incentives for treatment attendance;   Behavioral: Information
11 Completed
Has Results
Mesalamine to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Sexually Transmitted Diseases;   Immune System Diseases;   Lentivirus Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Mesalamine (5-aminosalicylic acid, Apriso);   Drug: Placebo
12 Completed Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Conditions: Acquired Immunodeficiency Syndrome;   Infant, Newborn;   Anemia;   Neutropenia;   HIV Infections
Intervention: Drug: cotrimoxazole
13 Completed GSK1349572 Relative Bioavailability Study
Condition: HIV Infections
Interventions: Drug: GSK1349572 formulation AP;   Drug: GSK1349572 formulation AW;   Drug: GSK1349572 formulation AX
14 Recruiting HIV Fat Redistribution and the Evaluation of Brown Fat
Condition: HIV Infections
Intervention:
15 Active, not recruiting Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
16 Completed Reducing HIV Risk Among Mexican Youth
Conditions: HIV Infections;   AIDS;   Sexually Transmitted Diseases
Interventions: Behavioral: Adolescent Safer Sex Intervention;   Behavioral: Parent Safer Sex Communication Intervention;   Other: Adolescent Health Promotion Control Condition;   Other: Parent Health Promotion Control Condition
17 Recruiting Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
18 Completed Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
Conditions: HIV;   Cardiovascular Disease
Intervention:
19 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
20 Completed A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
Condition: HIV-1 Infection
Intervention: Drug: Bevirimat

Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results
Indicates status has not been verified in more than two years